These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25417830)

  • 21. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
    Walker CM; van Burik JA; De For TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Ramanathan M; Teira P; Battiwalla M; Barrett J; Ahn KW; Chen M; Green J; Laughlin M; Lazarus HM; Marks D; Saad A; Seftel M; Saber W; Savani B; Waller EK; Wingard J; Auletta JJ; Lindemans CA; Boeckh M; Riches ML
    Bone Marrow Transplant; 2016 Aug; 51(8):1113-20. PubMed ID: 27042847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation.
    Merindol N; Salem Fourati I; Brito RM; Grenier AJ; Charrier E; Cordeiro P; Caty M; Mezziani S; Malette B; Duval M; Alfieri C; Ovetchkine P; Le Deist F; Soudeyns H
    J Immunol; 2012 Nov; 189(10):5016-28. PubMed ID: 23034171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Unrelated umbilical cord blood transplantation as a treatment for children with malignant leukemia].
    Tang XF; Luan Z; Xu SX; Wu NH; Huang YZ; Wang K
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):5-8. PubMed ID: 18289460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
    Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
    Mikulska M; Raiola AM; Bruzzi P; Varaldo R; Annunziata S; Lamparelli T; Frassoni F; Tedone E; Galano B; Bacigalupo A; Viscoli C
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):92-9. PubMed ID: 21689774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.
    Teira P; Battiwalla M; Ramanathan M; Barrett AJ; Ahn KW; Chen M; Green JS; Saad A; Antin JH; Savani BN; Lazarus HM; Seftel M; Saber W; Marks D; Aljurf M; Norkin M; Wingard JR; Lindemans CA; Boeckh M; Riches ML; Auletta JJ
    Blood; 2016 May; 127(20):2427-38. PubMed ID: 26884374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
    Hussein AA; Al-Antary ET; Najjar R; Al-Hamdan DS; Al-Zaben A; Frangoul H
    Pediatr Blood Cancer; 2015 Jun; 62(6):1099-101. PubMed ID: 25346146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy.
    Rinehart M; Hochard E; Rockey M; Abhyankar S; Ganguly S; Lin T; McGuirk J; Shune L; Singh A; Aljitawi O
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):105-11. PubMed ID: 27013276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
    Nachbaur D; Clausen J; Kircher B
    Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.